The L-DOPA story revisited. Further surprises to be expected?.- The enigma of cell death in neurodegenerative disorders.- Impaired iron homeostasis in Parkinson's disease.- The molecular mechanism of dopamine-induced apoptosis: identification and charac te rization of genes that med iate dopamine toxicity.- Glyce raldehyde-3-phosp hate dehydrogenase in neurodegenerat ion and apoptosis signaling.- Import ance of familial Parkinson's disease and parkinsonism to the understand -
ing of nigraI degener at ion in sporadic Parkinson's disease.- cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6 hydroxydopamine models: implications for idiopathic Parkinson's disease.- Moni toring neurop rotection and restorative therapies in Parkinson's disease with PET.- Common properties for prop argylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of ( 2212; )deprenyl.- TV3326, a novel neuro protective dru g with cholinesterase and monoamine oxidase inhibito ry activities for the treatm ent of Alzheimer's disease.- Neurotoxins induce apoptosis in dopamine neurons: prot ection bei N-propargylamine- l(R)- and (5)-aminoi ndan, rasagi line and TV1022.- Homocysteine and alcoholism.- Neur orescuing effects of the GAPDH ligand CGP 34668.- The neuroprotective effects of CGP 34668 in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monke.- Neurotrophic effects of central nicotinic receptor activation.- Regulation of neuronal cell death and differentiation by NGF and IAP family members.- Insulin-like growth factor- 1 (IGF-1): a neuroprotective trophic factor acting via the Aktinase pathway.-GDF-15/MIC-1 a novel member of the TGF-? superfamily.- Changes in cytokines and neurotrophins in Parkinson's disease.- Psychiatric complications in Parkinson's disease.- Dementia with Lewy bodies: prevalance, clinical spectrum and natural history.- Neuronal degeneration and reorganization: a mutual principle in pathological and in healthy interactions of limbic and prefrontal
circuits.- Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment.- The serotonin transporter in Alzheimer's and Parkinson's disease.- Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.- Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis.- Glutamate excitotoxicity - a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?.- Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics.
